Gerardo Musuraca

12PUBLICATIONS
110CO-AUTHORS
Predictive and prognostic markersRadiation therapyCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cellular immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jul 24, 2026
Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial.

|Jun 25, 2026
Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed/Refractory Follicular Lymphoma.

|Mar 28, 2026
Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study.

Stefano Molica, Potito Rosario Scalzulli, Lydia Scarfò

|Mar 08, 2025
A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ study.

Alessandra Tucci, Alessandro Re, Chiara Pagani

|Mar 28, 2024
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study.

Francesca Romana Mauro, Potito Rosario Scalzulli, Lydia Scarfò

|Nov 25, 2023
Correction: Bocci et al. Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma. J. Clin. Med. 2022, 11, 7162.

Guido Bocci, Sabrina Pelliccia, Paola Orlandi

Pageof 2

Frequent Collaborators

5 joint publications

Simone Ferrero

4 joint publications

Francesco Merli

4 joint publications

Federica Cavallo

4 joint publications

Stefan Hohaus